Advertisement
News
Advertisement

ImmuNext licenses potential cancer drug to Janssen

Wed, 09/05/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

ImmuNext Inc., a Lebanon, N.H. company working on protein-based therapeutics to treat autoimmunity, cancer, transplantation rejection and infectious diseases, has licensed its technology in a deal potentially worth more than $150 million.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading